PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Nakamura, Kunio
TI  - BRAVO Analysis: Laquinimod Reduces Brain Atrophy in Patients with RRMS
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 9--9
VI  - 14
IP  - 29
4099  - http://mdc.sagepub.com/content/14/29/9.1.short
4100  - http://mdc.sagepub.com/content/14/29/9.1.full
AB  - Laquinimod, an oral immunomodulator under development for the treatment of multiple sclerosis (MS), reduced whole brain atrophy in the ALLEGRO and BRAVO trials [Vollmer T et al. Neurology. 2012]. This study analyzed the effect of laquinimod on the percent volume change in gray and white matter in the phase 3 BRAVO trial [Vollmer T et al. J Neurol. 2014], using a newly developed, longitudinal image analysis technique.